OHSU Knight Cancer Institute
Eric Roeland, M.D., FAAHPM
This phase II trial tests how well olanzapine may work in managing cancer cachexia in patients experiencing advanced solid tumor cancer-associated appetite loss while receiving non-curative cancer therapy. Loss of appetite ("anorexia") in the setting of cancer is a key feature of "cachexia," a syndrome associated with loss of weight and muscle as well as weakness and fatigue. Olanzapine is a type of drug that targets key neurotransmitters (a type of molecule used by the brain to transmit messages to the rest of the body) that may stimulate appetite, restore caloric intake, minimize weight loss, and improve quality of life.
Advanced Malignant Solid Neoplasm
Biospecimen Collection
Computed Tomography
Olanzapine
Placebo Administration
Questionnaire Administration
Phase 2
PRIMARY OBJECTIVE: I. To assess the effect of olanzapine versus placebo for decreasing cancer-associated anorexia at 2 weeks for patients with advanced cancer receiving systemic therapy. SECONDARY OBJECTIVE: I. To evaluate the longitudinal impact of olanzapine versus placebo over 6 weeks on food intake, anthropometric measures, physical function, patient-reported symptoms, quality of life, toxicity, and healthcare utilization. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive 5mg of olanzapine orally (PO) nightly for six weeks on study. Patients may also undergo an optional computed tomography (CT) scan and blood sample collection on the study. ARM II: Patients receive placebo PO nightly for six weeks and then receive 5mg of olanzapine PO nightly for 6 weeks (i.e., wait-list control). Patients may also undergo an optional CT scan and collection of blood samples on the study.}}
Study Type : | Interventional |
Estimated Enrollment : | 44 participants |
Masking : | Double |
Primary Purpose : | Supportive Care |
Official Title : | ACTO: A Phase II, Randomized, Placebo-Controlled Study Evaluating Olanzapine in the Management of Cancer Cachexia |
Actual Study Start Date : | January 31, 2024 |
Estimated Primary Completion Date : | November 1, 2024 |
Estimated Study Completion Date : | November 1, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm I (olanzapine, optional biospecimen collection) Patients receive olanzapine PO for six weeks on study. Patients may also undergo an optional CT scan and blood sample collection on the study. |
Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Olanzapine Other: Questionnaire Administration |
Placebo Comparator: Arm II (placebo, olanzapine, optional biospecimen collection) Patients receive placebo PO for six weeks and then receive olanzapine PO for 6 weeks. Patients also undergo an optional CT scan and collection of blood samples on study. |
Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Olanzapine Drug: Placebo Administration |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239